A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors
Document Type
Abstract
Publication Date
11-1-2023
Keywords
oregon; chiles
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Pharmacy
COinS
Comments
Moser JC, Opyrchal M, Rivera IR, Bilen MA, Curti B, Puzanov I, Morris K, Nirschl CJ, Park S, Bruno M, Windt P, Subramanian KK, Chopra SS, Isaacs R. SITC Annual Meeting; November 1-5; San Diego, CA. 2023;11(Suppl 1): 737